Why is Windlas Biotech falling/rising?

As of 18-Sep, Windlas Biotech Ltd is currently priced at Rs 961.50, reflecting a decline of Rs 12.8 or 1.31%. The stock has been underperforming recently, having fallen consecutively for the last three days, resulting in a total drop of 3.85% during this period. Additionally, it has underperformed its sector by 2.36% today. The stock's performance over the past week shows a decrease of 3.65%, and over the past month, it has declined by 9.77%. Despite a positive annual return of 10.00%, the stock's recent movement is influenced by its higher trading volume near its intraday low of Rs 950.9 and its position relative to moving averages, being higher than the 100-day but lower than the shorter-term averages. The company's low debt-to-equity ratio and strong quarterly financial results, including record net sales and profits, suggest a fair valuation; however, the high PEG ratio of 3.7 indicates potential overvaluation compared to its peers.
Broader market context shows that while Windlas Biotech has generated a 10.00% return over the past year, it has underperformed the benchmark Sensex, which has risen by 6.24% year-to-date. The stock's recent struggles are compounded by a significant decline in short-term performance, contrasting sharply with the Sensex's 1.80% gain over the past week. This divergence highlights the stock's challenges in maintaining investor confidence, despite its historical outperformance over three years and consistent returns. The rising investor participation, as indicated by increased delivery volume, may provide some support, but the overall market sentiment appears to be weighing on the stock's price.